#1 Clinical Trials Search in Europe

Migalastat

Migalastat, also known as AT1001 or Galafold, is an investigational drug being studied as a potential treatment for Fabry disease. This rare genetic disorder affects the body’s ability to break down certain fats, leading to their buildup in various organs. Clinical trials are evaluating migalastat’s safety, effectiveness, and how it works in the body of patients with Fabry disease. These studies aim to determine if migalastat can improve symptoms and quality of life for people living with this condition.

Table of Contents

What is Migalastat?

Migalastat, also known by its brand name Galafold or research name AT1001, is a medication used to treat Fabry disease[1]. Fabry disease is a rare genetic disorder that affects the body’s ability to break down certain fatty substances, leading to their buildup in various organs and tissues[2].

This medication is designed to help patients with specific genetic mutations associated with Fabry disease. It works differently from traditional enzyme replacement therapy (ERT) and offers an oral treatment option for eligible patients[3].

How Migalastat Works

Migalastat is known as a pharmacological chaperone. This means it helps correct the function of a specific enzyme in the body called α-galactosidase A (α-Gal A). In Fabry disease, this enzyme doesn’t work properly due to genetic mutations[4].

The medication works by:

  1. Binding to the defective α-Gal A enzyme
  2. Helping the enzyme fold into its correct shape
  3. Guiding the enzyme to where it’s needed in the cell
  4. Increasing the enzyme’s activity to break down fatty substances

By enhancing the activity of α-Gal A, migalastat helps reduce the buildup of harmful substances in the body’s cells, potentially slowing down the progression of Fabry disease[5].

Treating Fabry Disease with Migalastat

Migalastat is specifically used to treat Fabry disease in patients who have certain amenable mutations in their GLA gene. An amenable mutation is a genetic change that allows migalastat to work effectively[3].

Fabry disease can affect various parts of the body, including:

  • Heart: Migalastat may help improve heart structure and function in Fabry patients[2]
  • Kidneys: The medication might slow down the decline in kidney function often seen in Fabry disease[6]
  • Nervous system: It may help reduce pain and other neurological symptoms associated with the disease

Dosage and Administration

Migalastat is typically taken as an oral capsule. The most common dosage reported in clinical trials is:

  • 150 mg capsule
  • Taken once every other day
Some studies have explored different dosing regimens, but the every-other-day schedule is most common[7][8].

It’s important to note that migalastat should be taken on an empty stomach. Studies have shown that food can affect how the medication is absorbed by the body[7].

Clinical Studies on Migalastat

Numerous clinical trials have been conducted to evaluate the safety and effectiveness of migalastat. These studies have looked at various aspects, including:

  • Long-term safety and efficacy[6]
  • Effects on heart and blood vessel structure and function[2]
  • Impact on kidney function[6]
  • How food affects the absorption of the medication[7]
  • Use in both male and female patients with Fabry disease[9]

These studies have generally shown that migalastat can be effective in increasing α-Gal A enzyme activity in patients with amenable mutations, potentially leading to improvements in disease symptoms and organ function[5].

Potential Side Effects

Like all medications, migalastat can cause side effects. However, in clinical trials, severe side effects were relatively rare[4][5]. Common side effects may include:

  • Headache
  • Nasal congestion
  • Urinary tract infections
  • Nausea
  • Fever
It’s important to discuss any side effects you experience with your healthcare provider.

Special Considerations

There are some special considerations for using migalastat:

  • Pregnancy and breastfeeding: A study is ongoing to evaluate the safety of migalastat during pregnancy and breastfeeding[10]. If you’re pregnant, planning to become pregnant, or breastfeeding, discuss this with your doctor.
  • Genetic testing: Before starting migalastat, patients need to undergo genetic testing to confirm they have an amenable mutation[3].
  • Long-term use: Some studies have looked at the long-term use of migalastat, up to 48 months or more[8]. Your doctor will monitor you regularly during treatment.

Migalastat represents an important advancement in the treatment of Fabry disease, offering an oral medication option for patients with amenable mutations. However, it’s crucial to work closely with your healthcare team to determine if migalastat is the right treatment for you and to monitor its effectiveness over time.

Aspect Details
Drug Name Migalastat (also known as AT1001, Galafold)
Condition Studied Fabry Disease
Administration Oral capsule, typically 150 mg every other day or 3 days on/4 days off
Main Outcomes Studied Safety, tolerability, pharmacodynamics, enzyme activity, kidney function, heart structure and function, quality of life
Study Durations 12-24 weeks initial treatment, with extensions up to 96 weeks or longer
Participant Criteria Adults with confirmed Fabry disease and responsive genetic mutations
Key Measurements α-Gal A activity, GFR, left ventricular mass, Lyso-GB3 levels, adverse events

FAQ

  • What is migalastat and how does it work? Migalastat is an oral medication being studied to treat Fabry disease. It works by helping to stabilize and improve the function of the α-galactosidase A enzyme, which is deficient in people with Fabry disease. This may help reduce the buildup of harmful substances in the body's cells.
  • Who can participate in migalastat clinical trials? Clinical trials for migalastat typically include adult patients with confirmed Fabry disease and specific genetic mutations that are responsive to migalastat. Some studies focus on male participants, while others include both males and females. Eligibility criteria may vary between trials.
  • What are the main outcomes being studied in migalastat trials? The main outcomes being studied include safety, tolerability, and how the drug works in the body (pharmacodynamics). Researchers are measuring changes in enzyme activity, kidney function, heart structure and function, and quality of life. They're also monitoring for any side effects.
  • How is migalastat administered in clinical trials? In most trials, migalastat is given as an oral capsule. The dosage and frequency can vary, but common regimens include 150 mg every other day or daily dosing for 3 days followed by 4 days off each week. Some studies have explored different dose levels.
  • How long do migalastat clinical trials typically last? The duration of migalastat trials can vary. Initial treatment periods often last 12 to 24 weeks, with some studies including optional extension periods that can last up to 96 weeks or longer. This allows researchers to assess both short-term and long-term effects of the treatment.

Ongoing Clinical Trials on Migalastat

  • Study on the Safety of Migalastat for Patients with Fabry Disease and Severe Kidney Problems on Dialysis

    Recruiting

    3 1 1 1
    Investigated drugs:
    France Portugal Spain

  • Study comparing venglustat tablets with standard therapy for adult patients with Fabry disease and left ventricular hypertrophy

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia Denmark France Germany Greece +5

Glossary

  • Fabry Disease: A rare genetic disorder that affects the body's ability to break down certain types of fats, leading to their buildup in various organs and tissues.
  • α-Galactosidase A (α-Gal A): An enzyme that is deficient in people with Fabry disease. It's responsible for breaking down certain fats in the body.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Pharmacokinetics: The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Enzyme Replacement Therapy (ERT): A treatment approach for Fabry disease that involves providing patients with a functional version of the missing or deficient enzyme.
  • Genotype: The genetic makeup of an organism, which in Fabry disease refers to the specific mutation in the GLA gene.
  • Echocardiography: An imaging technique that uses sound waves to create pictures of the heart, used to assess heart structure and function in Fabry disease patients.
  • Glomerular Filtration Rate (GFR): A measure of kidney function that estimates how much blood passes through the glomeruli (tiny filters in the kidneys) each minute.
  • Lyso-GB3: A biomarker used to monitor Fabry disease progression and treatment effectiveness.
  • Quality of Life (QoL): A measure of an individual's overall well-being, including physical, mental, and social aspects, often assessed in clinical trials to determine the impact of treatment.

References

  1. https://clinicaltrials.gov/study/NCT00214500
  2. https://clinicaltrials.gov/study/NCT03949920
  3. https://clinicaltrials.gov/study/NCT01476163
  4. https://clinicaltrials.gov/study/NCT00283933
  5. https://clinicaltrials.gov/study/NCT00283959
  6. https://clinicaltrials.gov/study/NCT01458119
  7. https://clinicaltrials.gov/study/NCT01489995
  8. https://clinicaltrials.gov/study/NCT00526071
  9. https://clinicaltrials.gov/study/NCT00304512
  10. https://clinicaltrials.gov/study/NCT04252066